Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4867824 | 0.79 | FFAR4 (0.38) | FFAR1 | |
| SCHEMBL6751378 | 0.78 | — | — | |
| SCHEMBL14152416 | 0.78 | L3MBTL1 (0.42) | L3MBTL1TDP1GRM2SLC6A2SLC6A4 | |
| SCHEMBL6749753 | 0.77 | — | — | |
| SCHEMBL13313276 | 0.76 | L3MBTL1 (0.56) | L3MBTL1TDP1GRM2SLC6A2SLC6A4 | |
| SCHEMBL4863163 | 0.75 | L3MBTL1 (0.31) | L3MBTL1TDP1 | |
| SCHEMBL6747862 | 0.74 | NSD2 (0.38) | L3MBTL1TDP1SLC6A4KMT2AKDM4E | |
| SCHEMBL6749776 | 0.74 | S1PR1 (0.30) | L3MBTL1TDP1 | |
| SCHEMBL8753757 | 0.73 | L3MBTL1 (0.56) | L3MBTL1TDP1GRM2SLC6A3MEN1 | |
| SCHEMBL3237515 | 0.73 | L3MBTL1 (0.47) | L3MBTL1TDP1GRM2SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351452-B2 | Liquid crystalline compounds containing a biphenyl core | QINETIQ LIMITED (GB) | 2008-04-01 | — | — | US | disclosed |
| US-20050001200-A1 | Liquid crystalline compounds containing a biphenyl core | QINETIQ LIMITED (GB) | 2005-01-06 | — | — | US | disclosed |
| US-6673886-B2 | FOR INTRAOCULAR LENSES | BAUSCH & LOMB INCORPORATED | 2004-01-06 | — | — | US | disclosed |
| US-6657030-B2 | High refractive index and hydrophilic monomers, a crosslinker, an initiator and water | BAUSCH & LOMB INCORPORATED | 2003-12-02 | — | — | US | disclosed |
| US-6657032-B2 | High refractive index and hydrophilic monomers, a crosslinker, an initiator and water | BAUSCH & LOMB INCORPORATED | 2003-12-02 | — | — | US | disclosed |
| US-6657029-B2 | High refractive index monomer, greater amount of a hydrophilic monomer, crosslinker, and initiator; give water content; intraocular lenses | BAUSCH & LOMB INCORPORATED | 2003-12-02 | — | — | US | disclosed |
| WO-2003040074-A1 | LIQUID CRYSTALLINE COMPOUNDS CONTAINING A BIPHENYL CORE | QINETIQ LIMITED (GB) | 2003-05-15 | — | — | WO | disclosed |
| US-20020049290-A1 | High refractive index hydrogel compositions for ophthalmic implants | VANDERBILT DAVID P (US) | 2002-04-25 | — | — | US | disclosed |
| US-20020042483-A1 | High refractive index hydrogel compositions for ophthalmic implants | VANDERBILT DAVID P (US) | 2002-04-11 | — | — | US | disclosed |
| US-20020042484-A1 | High refractive index hydrogel compositions for ophthalmic implants | BAUSCH & LOMB MEXICO, S.A. DE C.V. (MX) | 2002-04-11 | — | — | US | disclosed |
| US-20020037984-A1 | High refractive index hydrogel compositions for ophthalmic implants | VANDERBILT DAVID P (US) | 2002-03-28 | — | — | US | disclosed |
| US-6329485-B1 | FOR INTRAOCULAR LENSES | BAUSCH & LOMB INCORPORATED | 2001-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050001200-A1 | Liquid crystalline compounds containing a biphenyl core | YBX1, AFF1, AFF2 | L3MBTL1 409/4885TDP1 2471/4885GRM2 2417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.